Today: 9 April 2026
Subscribe
Browse Category

Biotechnology 26 September 2025 - 15 October 2025

Arcadia Biosciences Stock Rockets Amid Trade News – What’s Behind RKDA’s Wild Ride?

Arcadia Biosciences Stock Rockets Amid Trade News – What’s Behind RKDA’s Wild Ride?

Arcadia Biosciences (RKDA) stock soared 68% pre-market Oct 15 to $6.22 after President Trump tweeted about ending some cooking-oil trade with China, sparking a sector rally. The company’s Q2 revenue rose 11% to $1.455 million, all from Zola coconut water, but it posted a $4.46 million net loss due to a $4.5 million write-off on a note from Above Food. The planned merger with Roosevelt Resources remains pending.
15 October 2025
···
Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Genprex shares surged 41% after hours on Oct 14, 2025, to $0.36 following new data on its lead cancer therapy. The stock closed regular trading up 30% at $0.25, with volume spiking to 15 million shares. Market cap reached about $11 million. The company’s REQORSA gene therapy is in Phase 2 trials for lung cancer, with new preclinical data set for release at an upcoming oncology conference.
15 October 2025
···
Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

NTLA surged past $26 on Oct. 8, 2025, after positive Phase 1 data for its ATTR program showed sustained TTR protein knockdown and no new safety issues. Trading volume spiked to 17 million shares. Wall Street remains bullish, with most analysts rating NTLA a Buy and targets averaging $31.7. Intellia holds $630–707 million in cash and expects funding to last into 2027.
9 October 2025
··
Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Moderna closed at $27.34 on Oct 7, 2025, with a market cap near $11 billion. Q2 revenue fell 41% year-over-year to $142 million, and the company posted a net loss of $0.8 billion. U.S. and EU regulators limited updated COVID booster use, narrowing near-term revenue prospects. Analysts’ 12-month price targets remain high, but sales forecasts have repeatedly missed expectations.
8 October 2025
··
Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Why Intellia Therapeutics’ Stock Could Be a Gene‑Editing Goldmine in 2025 – Deep Dive into NTLA’s Prospects

Intellia shares surged to $26.14 on Oct. 8, up 72.6% over the past month, after Phase 1 data showed its CRISPR therapy reduced serum TTR by 92% at 24 months. The company reported Q2 revenue of $14.2 million and a narrowed net loss per share of $0.98. Cash reserves stood at $630 million. Analyst consensus rates the stock a “Moderate Buy” with targets averaging $27–34.
8 October 2025
··
CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

CRISPR Therapeutics (NASDAQ: CRSP) closed at $77.73 on Oct. 8, 2025, up 10% for the day and nearly 20% for the month. Trading volume reached 3.1 million shares, with the price moving between $70.77 and $78.38. The company’s market cap stood at $6.2 billion, and analysts’ average one-year price target was $81. CRSP remains pre-profit, reporting a Q2 net loss of $208.5 million on $0.9 million in revenue.
8 October 2025
·
Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia’s NTLA-2001 gene editing therapy cut TTR protein by about 90% for three years in transthyretin amyloidosis patients, with improved outcomes and no new safety issues, according to data presented Sept. 25 and published in NEJM. Enrollment finished for the Phase 3 HAELO trial of NTLA-2002, with top-line results expected in 1H 2026. Intellia stock is up over 60% in 2025. Q2 revenue more than doubled to $14.25 million.
8 October 2025
···
AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

Recursion Pharmaceuticals’ stock jumped 16% to $6.08 on October 8, 2025, after falling over 5% the previous day. The company uses AI to accelerate drug discovery and recently reported Q2 revenue of $19.2 million, up 33% year-over-year, but posted a net loss of $171.9 million. Recursion holds about $534 million in cash. Recent moves include acquiring Exscientia and cutting several pipeline programs.
8 October 2025
···
No-Revenue Biotech Soars 64,000% – Is Regencell (RGC) a Breakthrough or a Bubble?

No-Revenue Biotech Soars 64,000% – Is Regencell (RGC) a Breakthrough or a Bubble?

Regencell Bioscience shares soared over 64,000% in 2025, peaking at $83.60 before plunging 74% to around $17–18 by October, with a market cap near $8.5 billion. The stock jumped again in early October after S&P Global BMI Index inclusion and positive Phase II trial data showing a 37% improvement in ADHD/ASD symptoms. Regencell remains unprofitable with no revenue. Analysts maintain a “Strong Sell” rating.
7 October 2025
··
Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025)

Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025)

Spruce Biosciences shares soared over 1,300% after the FDA granted breakthrough therapy designation to its lead drug for Sanfilippo Syndrome Type B. Trading was repeatedly halted amid a flood of investor interest, including public backing from Martin Shkreli. The company, recently relisted on Nasdaq, faces ongoing financial strain with just $16.4 million in cash and no significant revenue.
7 October 2025
··
Tarsus Eyedrop Breakthrough Sends Stock Soaring: 10.9% Rally and Counting

Tarsus Eyedrop Breakthrough Sends Stock Soaring: 10.9% Rally and Counting

Tarsus (NASDAQ:TARS) surged 10.9% to $65.17 on Oct. 3, 2025, after reporting Q2 net product revenue of $102.7 million, up 152% year-over-year, driven by XDEMVY eyedrop sales. Shares have climbed 31% in the past month and 84% over the year. Wall Street consensus rates the stock a “Buy,” with average 12-month targets near $71. Losses are narrowing as sales rise and cash reserves remain strong.
3 October 2025
···
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (CDTX) Stock Soars After $339M BARDA Flu-Drug Deal – Is CD388 the Next Big Flu-Fighter?

Cidara shares jumped 5.7% to $104.13 Friday morning, nearing a 52-week high after winning a BARDA award worth up to $339 million for its flu drug CD388. The stock is up over 200% year-to-date, with analysts raising price targets as high as $173. Cidara reported $516.9 million in cash and a Q2 net loss of $25.7 million. Short interest stands at 11.3% of float.
3 October 2025
··
Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

GRAL shares surged to $69.14 intraday on Oct 3, up nearly 6.8% and about 248% year-to-date. Market cap reached $2.3–2.5 billion, a 472% jump since mid-2024, despite ongoing losses and negative EPS. Wall Street consensus remains “Hold” with a $31.50 average price target, far below current levels. Investors await new PATHFINDER 2 trial data at ESMO Congress later this month.
3 October 2025
···
Sarepta Therapeutics Stock Skyrockets After FDA U-Turn – Gene Therapy Drama Explained

Sarepta Therapeutics Stock Skyrockets After FDA U-Turn – Gene Therapy Drama Explained

The FDA on July 28, 2025, cleared Elevidys gene therapy shipments for ambulatory patients after finding no link to a child’s death, while Sarepta added black-box liver warnings. Sarepta’s Q2 revenue jumped 68% to $611.1 million, but shares plunged 85% YTD before rebounding to $22.35 after the FDA decision. The EU’s CHMP issued a negative opinion on Elevidys, delaying European approval. Sarepta cut 36% of its workforce in July.
3 October 2025
··
Nebius (NBIS) Stock Rockets on $17B Microsoft AI Deal – Explosive Growth & Outlook Revealed

Biotech Boom: NBIS Surges After Microsoft‑NeoCloud AI Deal – Is a New Bull Market Ahead?

The Nasdaq Biotechnology Index closed at 5,007.41 on Oct. 2, up 2.61%, its highest in over a year. The index traded between 4,911.94 and 5,039.83 and has ranged from 3,568.35 to 5,039.83 over the past 52 weeks. Biotech stocks have been volatile amid U.S. drug-pricing reform uncertainty, but recent AI deals and low valuations have drawn buyers.
2 October 2025
····
Billion-Dollar AI Bets and Biotech Breakthroughs: Top Tech News (Sept 27–28, 2025)

Billion-Dollar AI Bets and Biotech Breakthroughs: Top Tech News (Sept 27–28, 2025)

Nvidia will invest up to $100 billion to build 10 gigawatts of AI data centers for OpenAI, with the first 1 GW due by late 2026. The US cybersecurity agency issued an emergency directive after hackers breached at least one federal agency via Cisco firewall flaws, affecting hundreds of devices. The FDA approved Eli Lilly’s new breast cancer drug Inluriyo. The SEC loosened ETF rules, opening the door for new crypto ETFs.
28 September 2025
·········
Scholar Rock (SRRK) Just Hit a Regulatory Speed Bump—But the Long‑Term Muscle‑Building Story Still Has Legs

Scholar Rock (SRRK) Just Hit a Regulatory Speed Bump—But the Long‑Term Muscle‑Building Story Still Has Legs

The FDA issued a Complete Response Letter for Scholar Rock’s apitegromab on Sept. 23, citing only manufacturing issues at a third-party Indiana plant. Shares fell but analysts, including BMO and Leerink, maintained bullish outlooks, expecting a quick resolution. The EMA review continues, with a possible EU launch in late 2026. Scholar Rock reported $295 million in cash as of June 30.
26 September 2025
··
PSTV ERUPTS: UnitedHealthcare Backs Plus Therapeutics’ CNS Cancer Test—Stock Pops, Analysts Cheer, and the Real Winners Could Be Patients

PSTV ERUPTS: UnitedHealthcare Backs Plus Therapeutics’ CNS Cancer Test—Stock Pops, Analysts Cheer, and the Real Winners Could Be Patients

Plus Therapeutics’ CNSide Diagnostics signed a national agreement with UnitedHealthcare to cover its CNSide tumor cell test, effective Sept. 15, potentially reaching over 51 million members. PSTV shares surged about 60% premarket on Sept. 25 after the news. CNSide’s Houston lab secured CLIA accreditation the prior week. Plus Therapeutics also received $1.9 million in non-dilutive funding from CPRIT on Sept. 22.
26 September 2025
···
1 … 13 14 15 16

Stock Market Today

  • Wix.com (WIX) Faces Steep Share Price Decline, Valuation Close to Fair Value
    April 8, 2026, 6:30 PM EDT. Wix.com (WIX) stock has fallen sharply over multiple time frames, down 54.9% in one year and 74.3% in five years, reflecting significant market pressure. The stock recently closed at $74.40, showing a 17.8% drop in the past week. Despite this drop, a Discounted Cash Flow (DCF) model estimates Wix.com's intrinsic value at $69.88 per share, suggesting the current price trades about 6.5% above fair value. This implies investors may have factored in recent challenges, even as the company maintains positive cash flow projections. Wix.com's high price-to-earnings (P/E) ratio of 85.67 indicates strong growth expectations but also elevated risk. Investors should monitor valuation shifts amid ongoing volatility and changing market sentiment.

Latest article

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
Alphabet Stock (GOOG, GOOGL) Faces Split Fund Bets Ahead of Earnings After Fresh 13F Reports

Alphabet Stock (GOOG, GOOGL) Faces Split Fund Bets Ahead of Earnings After Fresh 13F Reports

8 April 2026
Zevenbergen Capital increased its Alphabet Class A share holdings by 27.4% in Q4, while Lombard Odier and Empirical Wealth Management reduced their Class C positions, according to April 7 filings. Alphabet will report first-quarter results on April 29. GOOG and GOOGL traded near $304 before Wednesday’s U.S. open. The filings reflect holdings as of December 31 and may not show current positions.
Go toTop